Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ExonHit launches mouse genome SpliceArray
Using its high resolution expression profiling analysis, ExonHit said that it identifies novel transcripts coding for new protein variants that may be involved in various genetic disorders such
Using its high resolution expression profiling analysis, ExonHit said that it identifies novel transcripts coding for new protein variants that may be involved in various genetic disorders such
With the launch of the Vist 7.7 training modules, Mentice said that it adds to the already wide range of training opportunities for carotid and coronary interventions –
Under the agreement Mr Velardi will continue the development on the selective depletion of allo-reactive T-cells from mismatched donors using Kiadis Pharma’s Atir. Kiadis Pharma is preparing for
The positive opinion from the Committee for Human Medicinal Products (CHMP), the committee responsible for the scientific assessment of new medicinal products, will be reviewed by the European
Sanofi-Aventis uses a range of Advanced Chemistry Development’s (ACD/Labs) analytical, predictive, and nomenclature tools such as ACD/SpecManager, ACD/Structure Design Suite, ACD/PhysChem Batch predictors, and ACD/Name. Additional support provided
According to the company, the product measurably improves radiologists’s reading times by employing the Dicom Digital Mammography standard. This standard enables the correct sequencing of scanned images on
The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time. They have asked Johnson & Johnson Pharmaceutical R&D (J&JPRD) to conduct additional audit
Using the grant funding from the National Institutes of Health (NIH), EpiVax will develop a pro-inflammatory and non-tolerogenic HIV vaccine delivery system based on the dendritic cell targeting
Adverse events observed in this study were similar to those seen in prior studies of subcutaneous Relistor. The positive outcome reported was from the double-blind, randomized placebo-controlled portion
Treague is collaborating with Medicines for Malaria Venture, a Geneva-based not-for-profit organization dedicated to reducing malaria, to develop RS(+) mefloquine for the treatment of malaria in countries where